The Montreal Model: Longer-Lasting Depression Relief

One of the persistent challenges with ketamine therapy has been durability. A single infusion can produce dramatic mood improvements within hours, but those effects often fade within days to weeks. The Montreal Model, developed by researchers at McGill University, directly addresses this limitation by integrating structured psychotherapy with ketamine treatment. A 2026 clinical trial demonstrated that this combined approach can sustain depression relief for eight weeks or longer.

For background on the Montreal Model's application to alcohol use disorder and TRD, see our earlier coverage of the protocol. This post focuses specifically on the sustained relief findings and the psychotherapy integration component.

What Makes the Montreal Model Different

Most ketamine treatment protocols focus on the pharmacological intervention: the dose, the route of administration, and the number of sessions. The Montreal Model treats ketamine as one component of a larger therapeutic framework. The key insight is that ketamine opens a window of enhanced neuroplasticity, and psychotherapy conducted during that window can produce deeper and more lasting changes than either intervention alone.

The model structures psychotherapy sessions to coincide with the period of peak neuroplastic activity following ketamine administration. Therapists work with patients on cognitive restructuring, emotional processing, and behavioral activation during the hours and days when the brain is most receptive to forming new patterns.

The 2026 Trial Results

The McGill University trial enrolled patients with moderate to severe depression and delivered the Montreal Model protocol over a defined treatment course. The headline findings were striking:

• 30% average reduction in depression scores, as measured by standardized rating scales, from baseline to end of treatment.
• Sustained improvement for 8+ weeks after the final ketamine session. This is notably longer than the typical duration of benefit seen with ketamine alone, which usually begins to fade within one to two weeks.
• Cumulative psychotherapy effects: Patients who engaged more actively in the psychotherapy components showed greater and more durable improvements, suggesting the therapy is not merely an add-on but a critical driver of sustained benefit.

Why Psychotherapy Integration Extends the Benefit

Ketamine's antidepressant mechanism involves rapid increases in brain-derived neurotrophic factor (BDNF) and the formation of new synaptic connections, particularly in the prefrontal cortex. This burst of neuroplasticity creates what researchers describe as a "window of opportunity" during which the brain is unusually receptive to learning and change.

Without structured therapeutic input during this window, the new neural connections may not consolidate around healthier thought patterns and behaviors. The depression-related neural circuits can reassert themselves as the acute pharmacological effects wear off.

The Montreal Model capitalizes on the neuroplasticity window by introducing targeted psychotherapeutic interventions at precisely the right time. Patients work through depressive thought patterns, process difficult emotions, and practice new coping strategies while their brains are primed for change. The result is that therapeutic gains become encoded in more durable neural pathways.

Clinical Implications

The Montreal Model findings have several practical implications for patients and clinicians:

For treatment planning: The data supports structuring ketamine therapy as part of an integrated treatment plan rather than as a standalone pharmacological intervention. This means coordinating ketamine sessions with psychotherapy appointments to maximize the overlap with the neuroplasticity window.

For expectations: Patients can reasonably expect longer-lasting benefits when they combine ketamine with active therapeutic engagement. The eight-week sustained improvement observed in the trial represents a meaningful extension beyond what ketamine alone typically provides.

For at-home treatment: The principles of the Montreal Model can be adapted to telehealth and at-home ketamine protocols. Patients receiving at-home sublingual ketamine can schedule therapy sessions during the days following their ketamine sessions to capture the neuroplasticity window.

How Isha Health Applies These Principles

Isha Health's treatment model incorporates the core insight of the Montreal Model: ketamine works best when paired with therapeutic support. Patients are connected with therapists through our ketamine therapist directory and encouraged to engage in psychotherapy alongside their ketamine sessions.

Our clinical outcomes data reflects the benefits of this integrated approach, with sustained improvements that extend well beyond the acute treatment phase.

What Patients Should Take Away

If you are considering ketamine therapy, the Montreal Model research suggests that your investment in the process matters as much as the medication itself. Engaging in psychotherapy, journaling, and intentional reflection during the days following each ketamine session can meaningfully extend and deepen your results.

The 30% depression score reduction and 8+ weeks of sustained benefit observed in the McGill trial were not produced by ketamine alone. They were produced by patients actively working with their therapists during a period when their brains were uniquely ready for change.

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.